Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C-Reference-Cited by-同舟云学术

Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C

Published:2017-09 Issue:9 Volume:49 Page:1029-1035
ISSN:1590-8658
Container-title:Digestive and Liver Disease
language:en
Short-container-title:Digestive and Liver Disease

Author:

Atsukawa Masanori,Tsubota Akihito,Kondo Chisa,Shimada Noritomo,Abe Hiroshi,Kato Keizo,Okubo Tomomi,Arai Taeang,Itokawa Norio,Iio Etsuko,Tanaka Yasuhito,Iwakiri Katsuhiko

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference30 articles.

1. Global epidemiology and genotype distribution of the hepatitis C virus infection;Gower;Journal of Hepatology,2014

2. Estimated global prevalence of hepatitis C virus infection;Perz,2004

3. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan;Kumada;Hepatology Research,2010

4. Diagnosis, management, and treatment of hepatitis C: an update;Ghany;Hepatology,2009

5. EASL Clinical Practice Guidelines: management of hepatitis C virus infection;European Association for the Study of the Liver;Journal of Hepatology,2011

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel formula used for predicting hepatocellular carcinoma after the achievement of sustained virologic response by direct-acting antivirals in patients with chronic hepatitis C;PLOS ONE;2023-09-21

2. Efficacy and Safety of Sofosbuvir and Ribavirin in an Italian Cohort of HCV Genotype 2 Elderly Cirrhotic Patients;The Eurasian Journal of Medicine;2022-06-03

3. Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older;BMC Gastroenterology;2022-04-28

4. Efficacy and safety of direct‐acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta‐analysis;Journal of Viral Hepatitis;2022-04-06

5. Real-world Safety and Effectiveness of 24-week Sofosbuvir and Ribavirin Treatment in Patients Infected with Rare Chronic Hepatitis C Virus Genotypes 3, 4, 5, or 6 in Japan;Internal Medicine;2022